Prime Medicine, Inc.PRMEEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
PRME Q4 FY2025 Key Financial Metrics
Revenue
$838.0K
Gross Profit
N/A
Operating Profit
$-48.6M
Net Profit
$-46.1M
Gross Margin
N/A
Operating Margin
-5800.5%
Net Margin
-5498.7%
YoY Growth
-61.6%
EPS
$-0.22
Prime Medicine, Inc. Q4 FY2025 Financial Summary
Prime Medicine, Inc. reported revenue of $838.0K (down 61.6% YoY) for Q4 FY2025, with a net profit of $-46.1M (down 9.0% YoY) (-5498.7% margin).
Key Financial Metrics
| Total Revenue | $838.0K |
|---|---|
| Net Profit | $-46.1M |
| Gross Margin | N/A |
| Operating Margin | -5800.5% |
| Report Period | Q4 FY2025 |
Prime Medicine, Inc. Annual Revenue by Year
Prime Medicine, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.6M).
Prime Medicine, Inc. Quarterly Revenue & Net Profit History
Prime Medicine, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $838.0K | -61.6% | $-46.1M | -5498.7% |
| Q3 FY2025 | $1.2M | +486.1% | $-50.6M | -4129.1% |
| Q2 FY2025 | $1.1M | — | $-52.6M | -4716.7% |
| Q1 FY2025 | $1.5M | +146.0% | $-51.9M | -3568.8% |
| Q4 FY2024 | $2.2M | — | $-42.3M | -1936.6% |
| Q2 FY2024 | $0 | — | $-55.3M | N/A |
| Q1 FY2024 | $591.0K | — | $-45.8M | -7743.0% |
| Q4 FY2023 | $0 | — | $-65.6M | N/A |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $591000 | $0 | $2.2M | $1.5M | $1.1M | $1.2M | $838000 |
| YoY Growth | N/A | N/A | N/A | N/A | 146.0% | N/A | 486.1% | -61.6% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $193.9M | $311.4M | $259.7M | $297.5M | $328.2M | $279.0M | $385.0M | $342.7M |
| Liabilities | $60.8M | $67.6M | $63.1M | $144.4M | $221.2M | $218.1M | $223.2M | $221.9M |
| Equity | $133.1M | $243.8M | $196.6M | $153.1M | $106.9M | $60.9M | $161.8M | $120.9M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-43.9M | $-67.7M | $-45.5M | $16.2M | $-48.9M | $-41.4M | $-35.0M | $-37.3M |